Leslie S Kurtzberg

Summary

Affiliation: Genzyme Corporation
Country: USA

Publications

  1. doi request reprint Bone marrow and tumor cell colony-forming units and human tumor xenograft efficacy of noncamptothecin and camptothecin topoisomerase I inhibitors
    Leslie S Kurtzberg
    Genzyme Corporation, 49 New York Avenue, Framingham, MA 01701, USA
    Mol Cancer Ther 7:3212-22. 2008
  2. doi request reprint Bone marrow CFU-GM and human tumor xenograft efficacy of three tubulin binding agents
    Leslie S Kurtzberg
    Genzyme Corporation, Framingham, MA 01701, USA
    Cancer Chemother Pharmacol 64:1029-38. 2009
  3. doi request reprint Genz-644282, a novel non-camptothecin topoisomerase I inhibitor for cancer treatment
    Leslie S Kurtzberg
    Genzyme Corporation, Framingham, Massachussetts 01701, USA
    Clin Cancer Res 17:2777-87. 2011
  4. ncbi request reprint Bone marrow CFU-GM and human tumor xenograft efficacy of three antitumor nucleoside analogs
    Rebecca G Bagley
    Genzyme Corporation, Framingham, MA 01701, USA
    Int J Oncol 34:1329-40. 2009

Detail Information

Publications4

  1. doi request reprint Bone marrow and tumor cell colony-forming units and human tumor xenograft efficacy of noncamptothecin and camptothecin topoisomerase I inhibitors
    Leslie S Kurtzberg
    Genzyme Corporation, 49 New York Avenue, Framingham, MA 01701, USA
    Mol Cancer Ther 7:3212-22. 2008
    ..This may be due to greater sensitivity of human bone marrow than mouse to the cytotoxicity of these agents. It may be possible to achieve similar levels of ARC-111 in patients as in mice allowing improved antitumor activity...
  2. doi request reprint Bone marrow CFU-GM and human tumor xenograft efficacy of three tubulin binding agents
    Leslie S Kurtzberg
    Genzyme Corporation, Framingham, MA 01701, USA
    Cancer Chemother Pharmacol 64:1029-38. 2009
    ..The bone marrow toxicity and human tumor xenograft activity of three tubulin-binding compounds, vincristine, paclitaxel, and tasidotin were compared...
  3. doi request reprint Genz-644282, a novel non-camptothecin topoisomerase I inhibitor for cancer treatment
    Leslie S Kurtzberg
    Genzyme Corporation, Framingham, Massachussetts 01701, USA
    Clin Cancer Res 17:2777-87. 2011
    ....
  4. ncbi request reprint Bone marrow CFU-GM and human tumor xenograft efficacy of three antitumor nucleoside analogs
    Rebecca G Bagley
    Genzyme Corporation, Framingham, MA 01701, USA
    Int J Oncol 34:1329-40. 2009
    ..Bringing together bone marrow toxicity data, tumor cell line cytotoxicity data, and human tumor xenograft efficacy provides valuable information for the translation of preclinical findings to the clinic...